EU Votes on Controversial Legislation on Hazardous Substances Used in Cosmetics

Why It Matters

Extending reformulation timelines eases pressure on beauty brands but may postpone the removal of hazardous chemicals, creating a tension between economic flexibility and public health protection across the EU cosmetics market.

Key Takeaways

• EU extends reformulation deadline to 2.5 years for CMR substances
• Derogations can stretch compliance time to over six years
• Industry sees plan as balanced, improving predictability
• NGOs call delays unacceptable, fearing health risks
• Proposed oral carcinogen exemption dropped after MEP opposition

Pulse Analysis

The European Union’s cosmetics framework has long hinged on the classification of substances as carcinogenic, mutagenic or toxic to reproduction (CMR). Under current law, any product containing a CMR ingredient must be withdrawn within 18 months of classification, unless a derogation is granted. This regime, overseen by the European Chemicals Agency, aims to safeguard consumers while giving manufacturers a clear, albeit tight, window to reformulate. However, the rapid pace of scientific assessment and the sheer variety of fragrance and colour additives have left many firms scrambling to meet the deadline.

The Omnibus VI proposal, now before the European Parliament, seeks to soften that pressure by extending the standard reformulation period to roughly two and a half years. It also introduces a flexible derogation mechanism that can push compliance beyond six years for particularly complex substances. Industry representatives, such as France’s FEBEA, argue the amendment restores predictability and allows for more robust safety assessments of alternatives. They point to examples like ethanol, which poses negligible risk in hand gels despite its broader toxic profile, to illustrate the nuanced risk‑based approach the proposal endorses.

Critics, including NGOs like Générations Futures, warn that the extended timelines could keep hazardous chemicals on shelves longer, undermining the EU’s reputation for stringent consumer protection. The rejection of a controversial exemption for oral or inhalation carcinogens reflects lingering political resistance to diluting health safeguards. As global supply chains increasingly converge on EU standards, the outcome of this vote will ripple beyond Europe, influencing formulation strategies for multinational beauty brands and potentially reshaping regulatory benchmarks worldwide.